PTC THERAPEUTICS INC (PTCT)
US69366J2006 - Common Stock
Taking everything into account, PTCT scores 2 out of 10 in our fundamental rating. PTCT was compared to 588 industry peers in the Biotechnology industry. PTCT has a bad profitability rating. Also its financial health evaluation is rather negative. PTCT is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year PTCT has reported negative net income.
In the past year PTCT has reported a negative cash flow from operations.
PTCT had negative earnings in each of the past 5 years.
In the past 5 years PTCT always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of PTCT (-33.06%) is better than 68.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -33.06% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-30.95%
ROA(5y)-25.64%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of PTCT (93.01%) is better than 94.87% of its industry peers.
In the last couple of years the Gross Margin of PTCT has remained more or less at the same level.
PTCT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 93.01% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.7%
GM growth 5Y-0.47%
2. Health
2.1 Basic Checks
PTCT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PTCT has been increased compared to 1 year ago.
PTCT has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, PTCT has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -1.50, we must say that PTCT is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -1.50, PTCT perfoms like the industry average, outperforming 51.97% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.5 |
ROIC/WACCN/A
WACC5.6%
2.3 Liquidity
A Current Ratio of 2.02 indicates that PTCT has no problem at all paying its short term obligations.
PTCT has a Current ratio of 2.02. This is in the lower half of the industry: PTCT underperforms 77.27% of its industry peers.
A Quick Ratio of 1.97 indicates that PTCT should not have too much problems paying its short term obligations.
PTCT's Quick ratio of 1.97 is on the low side compared to the rest of the industry. PTCT is outperformed by 76.07% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.02 | ||
| Quick Ratio | 1.97 |
3. Growth
3.1 Past
PTCT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 10.78%, which is quite good.
PTCT shows a strong growth in Revenue. In the last year, the Revenue has grown by 34.23%.
Measured over the past years, PTCT shows a very strong growth in Revenue. The Revenue has been growing by 28.79% on average per year.
EPS 1Y (TTM)10.78%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q87.3%
Revenue 1Y (TTM)34.23%
Revenue growth 3Y35.04%
Revenue growth 5Y28.79%
Revenue growth Q2Q83.43%
3.2 Future
The Earnings Per Share is expected to grow by 14.83% on average over the next years. This is quite good.
The Revenue is expected to grow by 1.86% on average over the next years.
EPS Next Y8.33%
EPS Next 2Y10.66%
EPS Next 3Y17.45%
EPS Next 5Y14.83%
Revenue Next Year-35.76%
Revenue Next 2Y-18.75%
Revenue Next 3Y-6.88%
Revenue Next 5Y1.86%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
PTCT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PTCT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
PTCT's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. PTCT is cheaper than 94.02% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 193.6 |
4.3 Compensation for Growth
A more expensive valuation may be justified as PTCT's earnings are expected to grow with 17.45% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.66%
EPS Next 3Y17.45%
5. Dividend
5.1 Amount
PTCT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PTC THERAPEUTICS INC
NASDAQ:PTCT (4/18/2024, 7:15:49 PM)
After market: 24.69 0 (0%)24.69
-0.47 (-1.87%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.89B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -33.06% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 93.01% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.02 | ||
| Quick Ratio | 1.97 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)10.78%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y8.33%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)34.23%
Revenue growth 3Y35.04%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y